Feedback

Browsing by C

Use an asterisk (*) for partial word searches (e.g. pemph*)

418 results found.

1.
2.
3.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

4.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

5.
6.
7.
Ordering Recommendation:  

Use to detect insulin secretion. Do not use to diagnose diabetes mellitus.

8.
9.
10.
11.
Ordering Recommendation:  

Aids in the detection of insulinoma. May aid in distinguishing type 1 from type 2 diabetes mellitus (DM) in ambiguous cases. Do not use to diagnose DM.

12.
Ordering Recommendation:  

Preferred test to detect acute phase inflammation (eg, autoimmune diseases, connective tissue disease, rheumatoid arthritis, infection, or sepsis).

DO NOT ORDER for cardiovascular disease (CVD) risk assessment. Test for CVD risk assessment is C-Reactive Protein, High Sensitivity (0050182).

13.
Ordering Recommendation:  

Not recommended for general cardiovascular disease risk assessment in asymptomatic adults. May aid in CVD risk stratification in specific populations.

14.
15.
16.
17.
18.
19.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

20.
Ordering Recommendation:  

Recommended for occupation exposure monitoring. This panel includes cadmium in blood and urine as well as beta-2-microglobulin and provides exposure guidance in accordance with OSHA regulations. To assess cadmium exposure in a non-occupational setting, urine cadmium (0025040) and/or blood cadmium (0099675) are preferred.

21.
Ordering Recommendation:  

Useful in the assessment of acute toxicity. For chronic exposure and the assessment of cadmium body burden, Cadmium, Urine (0025040) is preferred.

22.
23.
Ordering Recommendation:  

Useful in the assessment of chronic exposure and determination of cadmium body burden. For acute exposure, Cadmium, Blood (0099675) is preferred.

24.
Ordering Recommendation:  

Therapeutic monitoring for patients receiving caffeine therapy.

25.
Ordering Recommendation:  

Diagnose and monitor medullary thyroid carcinoma (MTC). Secondary test to assist in diagnosing multiple endocrine neoplasia type II and familial MTC.

26.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

27.
28.
29.
30.
31.
Ordering Recommendation:  

Determine composition of calculi.

32.
Ordering Recommendation:  

Determine composition and appearance of calculi.

33.
Ordering Recommendation:  

Use for kidney stone risk assessment and monitoring. Panel includes calcium, chloride, citric acid, creatinine, magnesium, oxalate, pH, phosphorus, potassium, sodium, and uric acid.

34.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

35.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

36.
Ordering Recommendation:  

May be used to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) and other functional disorders of the intestinal tract; may also be used for monitoring IBD activity.

37.
Ordering Recommendation:  

Use for diagnostic and prognostic information in patients with myeloproliferative neoplasms (MPNs) when JAK2 testing is negative.

38.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

39.
40.
41.
Ordering Recommendation:  

Diagnostic testing for Canavan disease.  Carrier screening for Canavan disease.

42.
Ordering Recommendation:  

Not a stand-alone test for ovarian cancer screening or diagnosis. May be used in the workup for and monitoring of epithelial ovarian cancer post therapy. Not recommended for breast cancer or germ-cell tumors.

43.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

44.
Ordering Recommendation:  

Monitor therapy and identify disease recurrence in individuals with a metastatic breast cancer diagnosis. Do not use for diagnosis or screening of breast cancer.

45.
Ordering Recommendation:  

Monitor therapy and identify disease recurrence in individuals with metastatic breast cancer. Do not use for diagnosis or screening of breast cancer.

46.
47.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

48.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

49.
Ordering Recommendation:  

Order to confirm a diagnosis of a hereditary cancer syndrome in an individual with a personal or family history that could be consistent with features of more than one cancer syndrome.

50.
51.
52.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

53.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

54.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

55.
Ordering Recommendation:  

Use in screening for carbapenem-resistant Enterobacteriaceae as recommended by CDC.

56.
57.
Ordering Recommendation:  

Identify alcohol abuse or abuse relapse; will detect chronic ethanol use (>=40 g/day for 2 weeks).

58.
Ordering Recommendation:  

Screening test for congenital disorders of glycosylation. For evaluation of alcohol abuse, order Carbohydrate Deficient Transferrin for Alcohol Use (0070412).

59.
60.
Ordering Recommendation:  

Use to diagnose increased carbon monoxide levels and its poisoning.

61.
62.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

63.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

64.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

65.
Ordering Recommendation:  

Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected.  Order with lupus anticoagulant (LA) (0030181) and anti-beta[2]GP1 IgG and IgM assay (0050321).

66.
Ordering Recommendation:  

Not a recommended panel for the diagnosis of antiphospholipid syndrome (APS). The combined IgG and IgM cardiolipin (aCL) test (0099344) is preferred.

67.
Ordering Recommendation:  

Preferred second-line testing for strong suspicion of seronegative antiphospholipid syndrome (APS). Order incrementally or concurrently with other non-criteria antiphospholipid antibody tests.

68.
Ordering Recommendation:  

Acceptable initial test for strong suspicion of antiphospholipid syndrome. Order with lupus anticoagulant (LA) (0030181) and anti-beta-2-glycoprotein 1 (anti-beta2GP1) IgG and IgM (0050321) assays. Combined IgG and IgM cardiolipin (aCL) antibody test (0099344) is preferred.

69.
Ordering Recommendation:  

Acceptable initial test when antiphospholipid syndrome (APS) is highly suspected. Order with lupus anticoagulant (LA) (0030181) and anti-beta-2-glycoprotein 1 (anti-beta[2]GP1) IgG and IgM (0050321) assays. Combined IgG and IgM cardiolipin (aCL) antibody test is preferred (0099344).

70.
Ordering Recommendation:  

Use if sequencing does not detect a mutation or to assess for a known familial deletion/duplication. This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x 2141) before ordering.

71.
Ordering Recommendation:  

Preferred test to assess for hereditary form of cardiomyopathy or arrhythmia.

72.
Ordering Recommendation:  

Acceptable test to assess for a hereditary form of cardiomyopathy or arrhythmia.

73.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

74.
Ordering Recommendation:  

Preferred test to follow-up presumptive results. For general screening, Carisoprodol Urine with Reflex to Quantitation (2012278) is preferred.

75.
Ordering Recommendation:  

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out carisoprodol and/or meprobamate exposure. For follow-up testing of a presumptive result, Carisoprodol and Meprobamate, Urine Quantitative (2012219) is preferred.

76.
Ordering Recommendation:  

Diagnose and monitor for fatty acid oxidation disorders and organic acidemias. Use in conjunction with urine organic acids and acylglycines testing.

77.
Ordering Recommendation:  

Preferred testing is free and total carnitine (0080068).

78.
Ordering Recommendation:  

• Useful in the diagnosis of primary carnitine deficiency (carnitine uptake defect).

•Monitor carnitine status.

79.
Ordering Recommendation:  

Useful in the diagnosis of primary carnitine deficiency (carnitine uptake defect) in conjunction with free and total plasma carnitine.

80.
Ordering Recommendation:  

Preferred testing is urine free and total carnitine (0081308).

81.
Ordering Recommendation:  

Preferred testing is free and total carnitine (0080068).

82.
Ordering Recommendation:  

Preferred testing is urine free and total carnitine (0081308).

83.
Ordering Recommendation:  

Use to assess fat malabsorption.

84.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

85.
Ordering Recommendation:  

Refer to Additional Technical Information document.

86.
Ordering Recommendation:  

Not recommended for evaluation of pheochromocytoma. Fractionated metanephrines in plasma (0080216) or urine (0080407) is recommended for assessment of pheochromocytoma. Use to evaluate clinical symptoms of excess catecholamine secretion. 

87.
Ordering Recommendation:  

Not a first-line test for suspected catecholamine-secreting neuroendocrine tumors (pheochromocytoma or neuroblastoma).

88.
Ordering Recommendation:  

Not a first-line test for suspected catecholamine-secreting neuroendocrine tumors (pheochromocytoma or neuroblastoma).

89.
90.
91.
Ordering Recommendation:  

For detection of CBFB-MYH11 fusion transcripts resulting from inv(16)/t(16;16) in patients with acute myeloid leukemia.

92.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

93.
Ordering Recommendation:  

Initial screening test when gastrointestinal stromal tumor (GIST) is suspected based on histology and location of tumor.

94.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

95.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

96.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

97.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

98.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

99.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

100.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

101.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

102.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

103.
Ordering Recommendation:  

Primarily aids the distinction between CLL/SLL and mantle cell lymphoma where CD200 is usually positive in CLL/SLL and negative in mantle cell lymphoma. CD200 is also positive in other B-cell lymphoproliferative disorders.

104.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

105.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

106.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

107.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

108.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

109.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

110.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

111.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

112.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

113.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

114.
Ordering Recommendation:  

Assess thymic function in suspected severe combined immunodeficiency (SCID), DiGeorge syndrome and other T- cell immune deficiency disorders. Evaluate immune reconstitution during highly active antiviral therapy (HAART) in HIV patients and post chemotherapy and hematopoietic cell transplant.

115.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

116.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

117.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

118.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

119.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

120.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

121.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

122.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

123.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

124.
125.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

126.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

127.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

128.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

129.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

130.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

131.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

132.
Ordering Recommendation:  

Order to confirm the clinical diagnosis of a CDKL5 mutation-related disorder (eg, infantile spasm syndrome or MECP2-negative atypical Rett syndrome).

133.
Ordering Recommendation:  

Order to confirm the clinical diagnosis of a CDKL5 mutation-related disorder (eg, infantile spasm syndrome or MECP2-negative atypical Rett syndrome).

134.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

135.
Ordering Recommendation:  

Initial test for prognostication of CN-AML.

136.
Ordering Recommendation:  

Do not use in the initial evaluation for celiac disease. Useful in ruling out celiac disease in selective clinical situations, such as equivocal small bowel histologic finding or individuals on a gluten-free diet not tested for celiac disease prior to starting the diet.

137.
Ordering Recommendation:  

Acceptable single screening test for celiac disease. Screen includes tTG antibodies IgA and IgG, and DGP antibodies IgA and IgG. Celiac Disease Reflexive Cascade (2008114) or Tissue Transglutaminase (tTG) Antibody, IgA (0097709) is the preferred test for screening patients with suspected celiac disease.

138.
Ordering Recommendation:  

Acceptable reflexive screening test for celiac disease. Screen includes tTG antibodies IgA and IgG, and DGP antibodies IgA and IgG. Celiac Disease Reflexive Cascade (2008114) or Tissue Transglutaminase (tTG) Antibody, IgA (0097709) is the preferred test for screening patients with suspected celiac disease.

139.
Ordering Recommendation:  

Preferred reflex screening test for celiac disease. May aid in monitoring adherence to gluten-free diet.

140.
Ordering Recommendation:  

May assist in evaluating for joint disease, systemic disease, or inflammation.

141.
142.
143.
Ordering Recommendation:  

Confirm suspected hereditary CNS cancer in individual with personal or family history of hereditary cancer. This test will not detect pathogenic PHOX2B polyalanine expansions causative for congenital hypoventilation syndrome.

144.
Ordering Recommendation:  

Useful for diagnosis of systemic sclerosis (SSc). Negative results do not rule out SSc. Preferred test is Systemic Scleroderma Comprehensive Panel (2013325).

145.
146.
Ordering Recommendation:  

Preferred test to confirm a clinical diagnosis and determine an etiology for cerebral cavernous malformation (CCM).

147.
Ordering Recommendation:  

Use to confirm a clinical diagnosis and determine an etiology for cerebral cavernous malformation (CCM).

148.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

149.
Ordering Recommendation:  

Identify bacteria in CSF.

150.
Ordering Recommendation:  

May be used as initial screening test in Wilson disease or copper transport disorders; preferred initial testing is panel with serum ceruloplasmin, serum copper, and free (direct) serum copper  (eg, Wilson Disease Screening Panel, Serum 0020598).

151.
Ordering Recommendation:  

Order to confirm a suspected diagnosis of a hereditary neuropathy or Charcot-Marie-Tooth (CMT) subtype other than CMT1/CMT1A. To confirm a diagnosis of CMT1/CMT1A, PMP22 gene deletion/duplication studies should be performed first.

152.
Ordering Recommendation:  

Recommended test for confirming a suspected diagnosis of Charcot-Marie-Tooth type 1 (CMT1) or 1A (CMT1A). PMP22 gene deletion/duplication analysis is performed first; if negative or inconclusive, testing reflexes to sequencing of 78 genes related to CMT and hereditary neuropathy.

153.
Ordering Recommendation:  

Appropriate initial test for confirming a suspected diagnosis of Charcot-Marie-Tooth type 1 (CMT1) or 1A (CMT1A). Mutations causing other types of CMT will not be detected. Can be used to test for a known familial PMP22 deletion or duplication associated with CMT1A or Hereditary Neuropathy with Liability to Pressure Palsies (HNPP).

154.
Ordering Recommendation:  

Prenatal test for fetuses with ultrasound findings suggestive of CHARGE syndrome, or for individuals who had a previous child with CHARGE syndrome, but do not know the specific mutation.

155.
Ordering Recommendation:  

Recommended test to confirm a clinical diagnosis or suspected diagnosis of CHARGE syndrome.

156.
157.
158.
159.
160.
Ordering Recommendation:  

Refer to Additional Technical Information document.

161.
Ordering Recommendation:  

Assess donor genotype.

162.
Ordering Recommendation:  

Assess donor genotype.

163.
Ordering Recommendation:  

Monitor engraftment of donor cells post allogenic stem cell transplantation.

164.
Ordering Recommendation:  

Monitor engraftment of donor cells post allogenic stem cell transplantation. Each cell sort must have a unique ARUP accession number.

165.
Ordering Recommendation:  

Assess recipient genotype.

166.
167.
168.
169.
170.
171.
Ordering Recommendation:  

Preferred test for detecting Chlamydia trachomatis and Neisseria gonorrhoeae in variety of specimens. This test does not include confirmation of positive results by an alternative nucleic acid target. If confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).

172.
Ordering Recommendation:  

Detect Chlamydia trachomatis and Neisseria gonorrhoeae in a variety of specimens. Positive results are confirmed using an alternate nucleic acid target.

173.
Ordering Recommendation:  

Viral transport media (eg, M4/UTM) is not preferred when testing for Chlamydia trachomatis and Neisseria gonorrhoeae by transcription-mediated amplification (TMA). Use of transport media other than Aptima specimen collection kit may result in reduced sensitivity. The preferred test is Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) (0060241) or if confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).

174.
Ordering Recommendation:  

SurePath media is not preferred when testing for Chlamydia trachomatis and Neisseria gonorrhoeae by transcription-mediated amplification (TMA). Use of transport media other than Aptima specimen collection kit may result in reduced sensitivity. The preferred test is Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) (0060241) or if confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).

175.
Ordering Recommendation:  

Can be used to detect Chlamydia trachomatis and Neisseria gonorrhoeae in ThinPrep specimens. This test does not include confirmation of positive results by an alternative nucleic acid target. If confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).

176.
Ordering Recommendation:  

Preferred test for detecting Chlamydia trachomatis in variety of specimens. This test does not include confirmation of positive results by an alternative nucleic acid target. If confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).

177.
Ordering Recommendation:  

Not recommended for routine detection of Chlamydia trachomatis (CT). Use to detect CT in medicolegal settings and to assess suspected treatment failure. May be considered for anatomic locations for which amplified testing has not been validated.

178.
179.
180.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

181.
182.
183.
184.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

185.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

186.
187.
Ordering Recommendation:  

Acceptable test for determining chronic exposure to organophosphate insecticides. Preferred test is Insecticide Exposure Panel (0020175).

188.
Ordering Recommendation:  

Rapid detection of aneuploidy involving chromosomes X, Y, 13, 18, and 21. Assay offered in conjunction with chromosome study.

189.
Ordering Recommendation:  

Aids in the diagnosis of systemic lupus erythematosus (SLE).

190.
Ordering Recommendation:  

Metal ion testing of joint fluid chromium may be complementary to serum testing but is not recommended. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Chromium, Serum (0098830).

191.
Ordering Recommendation:  

Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty. May be useful in the assessment of deficiency or overload. For the assessment of hexavalent chromium exposure, chromium in blood or RBCs is preferred.

192.
Ordering Recommendation:  

Chromium urine levels may be used to monitor short term exposure. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Chromium, Serum (0098830).

193.
Ordering Recommendation:  

Assay aids in monitoring but is not recommended for diagnosis of carcinoid tumors. Assay may be useful in monitoring nonsecretory sympathetic and parasympathetic  neuroendocrine tumors.

194.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

195.
Ordering Recommendation:  

Useful for the diagnosis of ataxia telangiectasia. Not appropriate for carrier testing or for diagnosing Fanconi anemia or similar breakage syndromes.

196.
Ordering Recommendation:  

Useful for the diagnosis of Fanconi anemia. DO NOT use in diagnosing ataxia telangiectasia or cell damage due to radiation or chemical exposures.

197.
Ordering Recommendation:  

Prenatal chromosome analysis on amniotic fluid when individual
•Is at increased risk for fetal aneuploidy based on maternal age, abnormal NIPT, abnormal multiple marker screening, or abnormal fetal ultrasound.
•Has a family history of chromosome abnormality or genetic disorder.
•Desires diagnostic testing instead of screening.

198.
Ordering Recommendation:  

Use to test amniotic fluid for the following indications:

Abnormal US findings

Abnormal prenatal screen

Fetal demise

Genomic microarray testing is performed on normal chromosome analysis results.  In cases with a normal karyotype, microarray studies reveal clinically relevant copy number variations (CNV) in ~6% of fetuses with an ultrasound anomaly and ~2% whose indication is advanced maternal age or positive aneuploidy screen.

199.
Ordering Recommendation:  

Diagnosis, prognosis, and monitoring of hematopoietic neoplasms.

200.
Ordering Recommendation:  

Diagnosis, prognosis, and monitoring of hematopoietic neoplasms. Microarray performed when karyotype results are reported as "normal" or "no growth."

201.
Ordering Recommendation:  

Prenatal chromosome analysis on chorionic villi when individual
•Is at increased risk for fetal aneuploidy based on maternal age, abnormal NIPT, abnormal multiple marker screening, or abnormal fetal ultrasound.
•Has a family history of chromosome abnormality or genetic disorder.
•Desires diagnostic testing instead of screening.

202.
Ordering Recommendation:  

Diagnosis, prognosis, and monitoring of hematopoietic neoplasms. This test is intended for oncology studies. For chromosome analysis to evaluate for a constitutional finding, order 2002289.

203.
Ordering Recommendation:  

Diagnosis, prognosis, and monitoring of hematopoietic neoplasms. Microarray performed when karyotype results are normal or no growth.

204.
205.
Ordering Recommendation:  

Confirm diagnosis of a known aneuploid syndrome or detect a chromosome translocation. This test is intended for constitutional studies. Refer to Cytogenomic SNP Microarray (2003414) for the PREFERRED FIRST-TIER test for intellectual disability, multiple anomalies, and autism-spectrum disorders. For chromosome analysis to evaluate for an oncology finding, order 2002290.

206.
Ordering Recommendation:  

Appropriate when there is a significant chance of trisomy. Chromosome studies will identify obvious numerical abnormalities, balanced chromosomal rearrangements, and large deletions/duplications. If chromosomes are normal, then testing reflexes to microarray.

207.
Ordering Recommendation:  

Order for standard chromosome analysis performed on cultured fetal or placental cells.

208.
Ordering Recommendation:  

• Useful to ensure the highest chance of obtaining meaningful results from fetal specimens.

• When tissue culture is unsuccessful or if the results of the chromosome analysis are normal, then testing reflexes to genomic microarray.

209.
210.
211.
Ordering Recommendation:  

May identify additional, useful  cytogenetic abnormalities in tissues that are not targeted by FISH assays.

212.
Ordering Recommendation:  

For rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y. If the FISH results are abnormal, the specimen will reflex to chromosome analysis for mechanism determination. If the FISH results are normal, the specimen will reflex to genomic microarray.

213.
Ordering Recommendation:  

For rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y. If the FISH results are abnormal, the specimen will reflex to chromosome analysis for mechanism
determination. If the FISH results are normal, the specimen will reflex to genomic microarray.

214.
Ordering Recommendation:  

Alternate test to detect prognostically important genomic abnormalities in CLL.

215.
216.
Ordering Recommendation:  

FISH probes for specific microdeletion/microduplication syndromes must be specified; if no specific syndrome is in question, genomic microarray should be ordered instead of screening multiple loci by FISH. 

217.
Ordering Recommendation:  

This is a process and hold test for bone marrow. Use when the clinical necessity of FISH is uncertain at the time of collection, so that CD138+ sorting on fresh specimen may be attempted and a pellet held for future FISH testing [eg, Multiple Myeloma Panel by FISH (2002294)].

218.
Ordering Recommendation:  

Rapid detection of aneuploidy involving chromosomes X, Y, 13, 18, and 21. Assay offered in conjunction with chromosome study.

219.
220.
Ordering Recommendation:  

Preferred test to assess common molecular causes of CGD.

221.
Ordering Recommendation:  

Tests for a common NCF1 mutation associated with autosomal recessive CGD.

222.
Ordering Recommendation:  

Molecular test to confirm a diagnosis or assess carrier status for X-linked CGD.

223.
224.
225.
226.
Ordering Recommendation:  

May use to predict survival in patients treated for metastatic breast, prostate, and colorectal cancers. May use to evaluate response to therapy.

227.
228.
229.
230.
Ordering Recommendation:  

Molecular (DNA) test to confirm a diagnosis of citrullinemia type II (or citrin deficiency) following clinical and/or biochemical presentation. To diagnose or rule out citrullinemia type II, refer to Amino Acids Quantitative by LC-MS/MS, Plasma (2009389).

231.
Ordering Recommendation:  

Molecular (DNA) test to confirm a diagnosis of citrullinemia type I following clinical and/or biochemical presentation. To diagnose or rule out citrullinemia type I, refer to Amino Acids Quantitative by LC-MS/MS, Plasma (2009389).

232.
233.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

234.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

235.
236.
237.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

238.
Ordering Recommendation:  

Reference method for diagnosis of C. difficile-associated diarrhea (turnaround time >=96 hrs). Preferred initial test is C. difficile toxin B gene (tcdB) by PCR.

239.
Ordering Recommendation:  

Do not order for diagnosis of C. difficile-associated diarrhea. For research interest/epidemiological purposes only.

240.
Ordering Recommendation:  

Not the preferred test for initial diagnosis of C. difficile-associated diarrhea. Preferred initial test is C. difficile toxin B gene (tcdB) by PCR (2002838).

241.
Ordering Recommendation:  

Recommended rapid, stand-alone diagnostic test for C. difficile-associated diarrhea.

242.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

243.
244.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

245.
Ordering Recommendation:  

Confirm suspected cobalamin/propionate/homocysteine metabolism-related disorder in individual with clinical symptoms and/or biochemical findings.

246.
Ordering Recommendation:  

May be used in the assessment of occupational exposure or toxic ingestion. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Cobalt, Serum (0025037).

247.
Ordering Recommendation:  

Metal ion testing of joint fluid chromium may be complementary to serum testing but is not recommended. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Cobalt, Serum (0025037).

248.
Ordering Recommendation:  

May be used in the assessment of occupational exposure or toxic ingestion. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty.

249.
Ordering Recommendation:  

May be useful in the assessment of acute exposure. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Cobalt, Serum (0025037).

250.
251.
Ordering Recommendation:  

Detect exposure to cocaine.

252.
Ordering Recommendation:  

Preferred test to follow-up presumptive results. For general screening, Cocaine Urine with Reflex to Quantitation (2012231) is preferred.

253.
Ordering Recommendation:  

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out cocaine exposure. For follow-up testing of a presumptive result, Cocaine, Urine Quantitative (0090359) is preferred.

254.
255.
256.
257.
258.
259.
260.
261.
262.
263.
Ordering Recommendation:  

Monitor replacement therapy in coenzyme Q deficiencies; not useful in coenzyme Q deficiency diagnosis.

264.
265.
Ordering Recommendation:  

Aid in histological diagnosis of Alport syndrome.

266.
267.
Ordering Recommendation:  

•For initial diagnosis and disease monitoring of epidermolysis bullosa acquisita.

• To further evaluate IgG BMZ antibodies, consider ordering with IgG antibody testing for epithelial BMZ (0092056) and bullous pemphigoid (BP180 & 230) antigens (0092566).

•Consider other types of BMZ antibody-associated disease testing (i.e., IgA epithelial BMZ  (0092057) and herpes gestationis factor (0092283)).

•To discriminate among the immunobullous skin diseases in patients suspected or known to have any type of immunobullous disease, order concurrently with testing for epithelial cell surface antibody (0090299) or refer to antibody panel tests for pemphigoid (0092001) and pemphigus (0090650).

268.
Ordering Recommendation:  

Indicated for individuals with metastatic colorectal cancer to guide treatment with anti-EGFR monoclonal antibodies (ie, cetuximab and panitumumab). Detects mutations in BRAF, KRAS, NRAS, extended KRAS, and PIK3CA.

269.
Ordering Recommendation:  

Initial screening for suspected deficiency in the classical complement pathway.

270.
Ordering Recommendation:  

Initial screening for suspected deficiency in the alternative complement pathway.

271.
Ordering Recommendation:  

Marker of nephritis/prediction of glomerular nephritis.

272.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 is low or absent and AH50 is normal and high suspicion remains for complement deficiency.

273.
Ordering Recommendation:  

Aids in the diagnosis of C1q deficiency.

274.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 is low or absent and AH50 is normal and high suspicion remains for complement deficiency.

275.
276.
277.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

278.
279.
Ordering Recommendation:  

Follow-up test for complement activity screening when  CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

280.
281.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

282.
283.
Ordering Recommendation:  

Follow-up test for complement activity screening when  CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

284.
285.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

286.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 is low or absent and AH50 is normal and high suspicion remains for complement deficiency.

287.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 and AH50 are low or absent and high suspicion remains for complement deficiency.

288.
Ordering Recommendation:  

Monitor rheumatologic disease.

289.
Ordering Recommendation:  

Follow-up test for complement activity screening when CH50 is normal and AH50 is low.

290.
Ordering Recommendation:  

Follow-up test for complement activity screening when both CH50 and AH 50 are low or absent.

291.
Ordering Recommendation:  

Follow-up test for complement activity screening when both CH50 and AH 50 are low or absent.

292.
293.
294.
295.
296.
Ordering Recommendation:  

•Not a first-line screening test for CAH.

•Order to confirm the diagnosis of CAH following suggestive biochemical testing.

•Genetic test on fetal samples for prenatal detection of CAH.

297.
Ordering Recommendation:  

Screen for 11-beta hydroxylase deficiency.

298.
Ordering Recommendation:  

Screen for 21-hydroxylase deficiency, the most common congenital adrenal insufficiency.

299.
Ordering Recommendation:  

Use to monitor treatment of individuals with classic or nonclassic congenital adrenal hyperplasia.

300.
Ordering Recommendation:  

Refer to Additional Technical Information document.

301.
Ordering Recommendation:  

Confirmatory tests for specific connective tissue disease.

302.
Ordering Recommendation:  

Diagnostic testing for GJB2-related nonsyndromic hearing loss. Carrier screening for GJB2-related nonsyndromic hearing loss.

303.
304.
305.
306.
307.
Ordering Recommendation:  

Aids in diagnosis of Contactin Associated Protein 2 (CASPR2) Antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Use to manage antibody-positive (CASPR2) individual following immunotherapy and/or plasmapheresis.

308.
Ordering Recommendation:  

May be useful when related serum or urine assessments are inconclusive. For the complete assessment of copper overload, Wilson Disease Screening Panel, Serum (0020598) is preferred.

309.
310.
Ordering Recommendation:  

May be useful for exposure monitoring or investigation. However, not recommended for clinical diagnostic purposes. Refer to Copper, Serum (0020096) or Copper, Serum Free (Direct) (0020596).

311.
Ordering Recommendation:  

May be useful in the assessment of copper overload or response to copper-reducing therapies. Directly measures the free (non-ceruloplasmin bound) fraction of copper. For the complete assessment of copper overload, Wilson Disease Screening Panel, Serum (0020598) is preferred.

312.
Ordering Recommendation:  

Useful in the assessment of deficiency or overload. Copper, Serum Free (Direct) (0020596) may be a more specific indicator of copper overload. For the complete assessment of copper overload, Wilson Disease Screening Panel, Serum (0020598) is preferred.

313.
Ordering Recommendation:  

Useful in the assessment of overload. For the complete assessment of copper overload, Wilson Disease Screening Panel, Serum (0020598) is preferred.

314.
315.
316.
317.
Ordering Recommendation:  

•Rule-out Cushing syndrome.

318.
Ordering Recommendation:  

Screen, diagnose, and monitor diseases associated with excess or deficient cortisol production.

319.
Ordering Recommendation:  

•Rule-out Cushing syndrome.

•Screen for thymic and bronchial carcinoid tumors.

320.
Ordering Recommendation:  

•Differential diagnosis of Cushing syndrome.

•Screen and diagnose primary and secondary adrenal insufficiency.

321.
322.
323.
Ordering Recommendation:  

Identify C diphtheriae in clinical specimens.

324.
Ordering Recommendation:  

Urine screening test for determining active exposure to nicotine and compliance with smoking-cessation programs. For determination of active, passive, and differentiation between nicotine replacement and tobacco use, Nicotine and Metabolites, Urine, Quantitative (0092356) is preferred.

325.
Ordering Recommendation:  

Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients.

326.
Ordering Recommendation:  

Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients. Recommend testing of acute and convalescent sera.

327.
328.
329.
330.
Ordering Recommendation:  

Initial test to diagnose or rule out creatine deficiency syndromes following clinical presentation. Order Creatine Disorders Panel, Urine (2002333), simultaneously for proper result interpretation.

331.
Ordering Recommendation:  

Initial test to diagnose or rule out creatine deficiency syndromes following clinical presentation. Order Creatine Disorders Panel, Serum or Plasma (2002328), simultaneously for proper result interpretation.

332.
Ordering Recommendation:  

Aids in determining the etiology of elevated total creatine kinase. Cardiac troponins [troponin I (0090613) or troponin T (0098803)] are the recommended tests for diagnosis and management of acute coronary syndrome. May aid in identifying the presence of macro creatine kinase.

333.
Ordering Recommendation:  

Cardiac troponins [troponin I (0090613) or troponin T (0098803)] are the recommended tests for diagnosis and management of acute coronary syndrome.

334.
Ordering Recommendation:  

Nonspecific indicator of muscle inflammation or damage.

335.
Ordering Recommendation:  

Molecular (DNA) test to confirm a diagnosis of creatine transporter deficiency syndrome when Creatine Transporter Deficiency (SLC6A8) Sequencing (2008615) does not identify a causative mutation. Carrier testing for individuals with a family history of a deletion or duplication in the SLC6A8 gene.

336.
Ordering Recommendation:  

Molecular (DNA) test to confirm a diagnosis of creatine transporter deficiency syndrome following clinical and biochemical presentation. To diagnose or rule out creatine deficiency syndromes, refer to Creatine Disorders Panel, Plasma or Serum (2002328), and Creatine Disorders Panel, Urine (2002333).

337.
Ordering Recommendation:  

Preferred molecular (DNA) test to confirm a diagnosis of creatine transporter deficiency syndrome following clinical and biochemical presentation. To diagnose or rule out creatine deficiency syndromes, refer to Creatine Disorders Panel, Plasma or Serum (2002328), and Creatine Disorders Panel, Urine (2002333).

338.
Ordering Recommendation:  

Monitor patients receiving creatine supplementation.

339.
Ordering Recommendation:  

•Monitor patients receiving creatine supplementation.

•May be useful when evaluating for possible creatine transporter deficiency; however, the preferred test is the urine panel for creatine disorders (2002333).

340.
341.
342.
343.
Ordering Recommendation:  

Screening test to evaluate kidney function.

344.
Ordering Recommendation:  

Aid in the diagnosis and prognostication of Crohn disease.

345.
346.
347.
348.
349.
350.
351.
Ordering Recommendation:  

Test for persistent diarrhea (>14 days) or known risk factors if Cryptosporidium spp is the suspected infectious agent.

352.
Ordering Recommendation:  

- Order concurrently with serum antibody testing and fixed tissue histopathology for assessment of patient with pruritic, urticarial, blistering and/or erosive disorders, including possible pemphigoid and pemphigoid variants, pemphigus and pemphigus subtypes, dermatitis herpetiformis, epidermolysis bullous acquisita, porphyria, and pseudoporphyria.

- Order concurrently with fixed tissue histopathology for assessment of patient with inflammatory, immune-mediated cutaneous disease, including possible lupus and lupus variants, vasculitis, drug reactions, lichen planus and lichenoid reactions.

353.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

354.
Ordering Recommendation:  

Monitor cyanide exposure.

355.
Ordering Recommendation:  

Highly specific serologic test that aids in the workup of suspected rheumatoid arthritis or undifferentiated inflammatory arthritides.  Rheumatoid Arthritis Panel (2003277) is preferred test.

356.
Ordering Recommendation:  

Diagnosis of mantle cell lymphoma in conjunction with morphology and immunohistochemical studies.

357.
358.
359.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

360.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

361.
Ordering Recommendation:  

Prognostication and monitoring in NSCLC.

362.
363.
Ordering Recommendation:  

Carrier screening for expectant individuals and those planning a pregnancy AND diagnostic testing for individuals with symptoms of classic CF.

364.
Ordering Recommendation:  

For individuals with suspected CF. This test is NOT indicated for routine obstetric screening. If individual is not symptomatic, order Cystic Fibrosis (CFTR) 165 Pathogenic Variants (2013661).

365.
Ordering Recommendation:  

For individuals with suspected CF. This test is NOT indicated for routine obstetric screening. If individual is not symptomatic, order Cystic Fibrosis (CFTR) 165 Pathogenic Variants (2013661).

366.
Ordering Recommendation:  

For fetal testing when both parents are known carriers of one of the variants on the CF 165 variants test OR fetus has an echogenic bowel.

367.
Ordering Recommendation:  

Use to detect a known large familial CFTR deletion or for symptomatic individuals who do not have 2 pathogenic variants detected by sequencing. This is a second tier test that REQURIES PERMISSION from an ARUP genetic counselor (800-242-2787, x 2141) before ordering.

368.
Ordering Recommendation:  

For individuals with suspected CF but without 2 pathogenic variants detected by the CF 165 pathogenic variants test.

369.
Ordering Recommendation:  

For individuals with suspected CF but without 2 pathogenic variants detected by the CF 165 pathogenic variants test.

370.
Ordering Recommendation:  

To aid in management of patients with cystic fibrosis.

371.
Ordering Recommendation:  

Detect presence of IgG antibodies to T. solium in serum if clinical suspicion of cysticercosis exists. Consider confirming positive results with Western blot antibody test.

372.
Ordering Recommendation:  

Detect the presence of CSF IgG antibodies to T. solium, if clinical suspicion of cysticercosis exists. Confirm positive results with IgG Western blot antibody test.

373.
Ordering Recommendation:  

Use for monitoring treatment of patients previously diagnosed with cystinuria. To diagnose or rule out cystinuria, refer to Cystinuria Panel (0081105) or Amino Acids Quantitative by LC-MS/MS, Urine (2009419).

374.
Ordering Recommendation:  

Initial test to diagnose or rule out cystinuria.

375.
Ordering Recommendation:  

•Assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP219.

•May aid in drug selection and dose planning for drugs metabolized by CYP219.

376.
Ordering Recommendation:  

•Assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2D9.

•May aid in drug selection and dose planning for drugs metabolized by CYP2D9.

377.
Ordering Recommendation:  

Assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2D6.

May aid in drug selection and dose planning for drugs metabolized by CYP2D6.

378.
Ordering Recommendation:  

•Assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP3A5.

•May aid in drug selection and dose planning for drugs metabolized by CYP3A5.

379.
Ordering Recommendation:  

Assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2D6, CYP2C9, CYP2C19, and CYP3A5. May aid in drug selection and dose planning for many drugs.

380.
Ordering Recommendation:  

Preferred test for FFPE tissue at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving

•Loss/gain of DNA

•Loss of heterozygosity (LOH)

Monitor disease progression and response to therapy.

381.
Ordering Recommendation:  

For detection of copy number alterations and loss of heterozygosity in FFPE specimens from products of conception.

382.
Ordering Recommendation:  

Preferred first-tier test for developmental delay, multiple anomalies, and autism-spectrum disorders. Testing is performed on peripheral blood.

383.
Ordering Recommendation:  

Diagnostic test designed to identify genomic abnormalities (eg, aneuploidy and microdeletions).
Performed on direct or cultured amniotic fluid and chorionic villus sampling (CVS) specimens.

384.
Ordering Recommendation:  

Preferred test for fresh specimens at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving

•Loss/gain of DNA

•Loss of heterozygosity (LOH)

Monitor disease progression and response to therapy.

385.
Ordering Recommendation:  

Preferred first-tier test for developmental delay, multiple anomalies, and autism-spectrum disorders. Testing is performed on buccal sample.

386.
Ordering Recommendation:  

Useful when chromosome and array tests would otherwise have been ordered concurrently. Assay may identify cytogenetically visible rearrangements and provide information regarding mechanism of gains and losses.

387.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

388.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

389.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

390.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

391.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

392.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

393.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

394.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

395.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

396.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

397.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

398.
Ordering Recommendation:  

Establish diagnosis for mass lesions accessible by fine needle aspiration.

399.
Ordering Recommendation:  

This test is used for all non-gynecologic sources EXCEPT specimens obtained by fine needle aspiration. For fine needle aspirate (FNA) specimens, refer to Cytology, Fine Needle Aspirate (2000443).

400.
Ordering Recommendation:  

Use for screening and detection of cervical cancer.

401.
Ordering Recommendation:  

May be used for routine 3-year interval cervical cancer screening test in all women. For 5-year interval testing. (cotest) in women 30-65 years, order with HPV test (2011942 or 2011937).

402.
Ordering Recommendation:  

For HPV testing, only FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep testing (2000136).

403.
Ordering Recommendation:  

For HPV testing, only FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep testing (2000138).

404.
Ordering Recommendation:  

•May be used for routine 3-year interval cervical cancer screening test in all women >=21 years.

•For 5-year interval testing (co-test) in women 30-65 years, order with HPV ThinPrep test (2011947 or 2007893).

405.
Ordering Recommendation:   Preferred FDA-approved test for 5-year interval testing (co-testing) in women >= 30 years.
406.
Ordering Recommendation:  

•Preferred FDA-approved test for routine cervical cancer screening test for women 21-<25 years.

•An option for 3-year cervical cancer screening intervals in women 25-65 years. For preferred co-testing panel, refer to (2000136). 

407.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

408.
Ordering Recommendation:  

Aids in discriminating between current and past cytomegalovirus infection in immunocompetent individuals.

409.
Ordering Recommendation:  

Detects past cytomegalovirus exposure. Not recommended for diagnosis in immunocompromised individuals.

410.
Ordering Recommendation:  

Order to aid in the diagnosis of cytomegalovirus (CMV) infection during pregnancy after initial testing for CMV IgM and IgG has been performed.

411.
Ordering Recommendation:  

Not recommended as a standalone test. If using serology testing, IgM combined with IgG is preferred. Do not use for diagnosis in immunocompromised individuals. Preferred test for detecting CMV infection is quantitative PCR (0051813).

412.
413.
Ordering Recommendation:  

Detects cytomegalovirus in whole blood or bone marrow but does not quantify viral load. Quantitative cytomegalovirus PCR (0051813) testing on patient plasma is preferred for most clinical indications.

414.
Ordering Recommendation:  

Detects cytomegalovirus but does not quantify viral load. Potentially useful for specimen types other than blood.

415.
Ordering Recommendation:  

Detects cytomegalovirus but does not quantify viral load.  Potentially useful for congenital screening of neonates for CMV-associated hearing loss.

416.
Ordering Recommendation:  

Preferred test for detecting cytomegalovirus infection and guiding post-transplant therapy.

417.
Ordering Recommendation:  

Aids in diagnosis of active cytomegalovirus infection. Molecular testing is generally preferred.

418.